Brésil - portugais - ANVISA (Agência Nacional de Vigilância Sanitária)

cosmed industria de cosmeticos e medicamentos s.a. - simeticona - adsorventes e antifiseticos intestinais simples

Brésil - portugais - ANVISA (Agência Nacional de Vigilância Sanitária)

cristÁlia produtos quÍmicos farmacÊuticos ltda. - nitroprusseto de sódio di-hidratado - vasodilatadores

Union européenne - portugais - EMA (European Medicines Agency)

koanaa healthcare gmbh - o imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agentes antineoplásicos - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. os pacientes que têm um baixo ou muito baixo risco de recorrência não deve receber tratamento adjuvante. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. exceto em recém-diagnosticados lmc em fase crónica, não há ensaios clínicos controlados demonstrando um benefício clínico ou aumento da sobrevivência para essas doenças.

Union européenne - portugais - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agentes antineoplásicos - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - etoricoxib - comprimido revestido por película - 30 mg - etoricoxib 30 mg - etoricoxib - genérico - duração do tratamento: curta ou média duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - etoricoxib - comprimido revestido por película - 30 mg - etoricoxib 30 mg - etoricoxib - genérico - duração do tratamento: curta ou média duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - etoricoxib - comprimido revestido por película - 90 mg - etoricoxib 90 mg - etoricoxib - genérico - duração do tratamento: curta ou média duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

towa pharmaceutical, s.a. - etoricoxib - comprimido revestido por película - 60 mg - etoricoxib 60 mg - etoricoxib - genérico - duração do tratamento: curta ou média duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - etoricoxib - comprimido revestido por película - 30 mg - etoricoxib 30 mg - etoricoxib - genérico - duração do tratamento: curta ou média duração

Portugal - portugais - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

neclife pt, unipessoal lda. - cefixima - comprimido revestido por película - 400 mg - cefixima 447.67 mg - cefixime - genérico - duração do tratamento: curta ou média duração